Anders D Hove Form 4/A Anacor Pharmaceuticals / Anders D Hove ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Hove Anders D

(Last) (First) (Middle)

C/O VENROCK

3340 HILLVIEW AVE.

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Anacor Pharmaceuticals, Inc. [ ANAC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/03/2015

4. If Amendment, Date of Original Filed (Month/Day/Year)
11/05/2015

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/03/2015		J		1,399,705(1)	D	$0	1,325,830	I	By Funds and LLC's(2)
Common Stock	11/03/2015		J		372,982(3)	A	$0	1,698,812	I	By Funds and LLC's(2)(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On November 3, 2015, Venrock Associates IV, L.P. ("VA4"), Venrock Partners, L.P. ("VP"), Venrock Entrepreneurs Fund IV, L.P. ("VEF4"), Venrock Healthcare Capital Partners, L.P. ("VHCP") and VHCP Co-Investment Holdings, LLC ("VHCP Co-Invest") (collectively, the "Venrock Funds") distributed an aggregate of 1,399,705 shares of the common stock of the Issuer to their respective partners pro rata based on their respective interests in the Venrock Funds (the "Distribution"). This Form 4 corrects the aggregate number of shares distributed in the Distribution and the number of shares held post-Distribution.

2. Following the Distribution, the Venrock Funds' shares are held as follows: 566,247 shares held by VA4, 115,475 shares held by VP, 13,913 shares held by VEF4, 447,957 shares held by VHCP and 182,238 shares held by VHCP Co-Invest. Venrock Management IV, LLC ("VM4"), Venrock Partners Management, LLC ("VPM") and VEF Management IV, LLC ("VEFM4") are the sole general partners of VA4, VP and VEF4, respectively, and may be deemed to beneficially own these shares. VHCP Management, LLC ("VHCP Management") is the general partner of VHCP and the manager of VHCP Co-Invest and may be deemed to beneficially own these shares. Anders Hove is a member of VM4, VPM and VEFM4 and a managing member of VHCP Management. Dr. Hove expressly disclaims beneficial ownership over all shares held by VA4, VP, VEF4, VHCP, VHCP Co-Invest, VM4, VPM, VEFM4 and VHCP Management except to the extent of his indirect pecuniary interest therein.

3. In the Distribution, VM4 received 180,193 shares, VPM received 36,797 shares, VEFM4 received 3,502 shares, and VHCP Management received 152,490 shares. Dr. Hove is a member of VM4, VPM and VEFM4 and a managing member of VHCP Management. Dr. Hove expressly disclaims beneficial ownership over all shares held by VM4, VPM, VEFM4 and VHCP Management except to the extent of his indirect pecuniary interest therein. For VM4, VPM, VEFM4 and VHCP Management, this represents a change in form of ownership from indirect to direct but does not represent a change in beneficial ownership.

Remarks:

	/s/ Anders D. Hove	11/12/2015
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.